]>
IRCT20210517051326N1 IRCT 2023-04-27 Shahid Beheshti University of Medical Sciences Effect of pentoxifillyn on COVID-19 Investigating the effect of Pentoxifylline drug on the clinical progression of covid-19 in patients with acute respiratory failure of moderate severity in the intervention and control groups 2022-05-22 anticipated 70 Complete https://irct.ir/trial/63654 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: White and black color cards are used. 35 white cards and 35 black cards are prepared and randomly selected and placed in sealed envelopes from 1 to 70, respectively, and with the arrival of each patient, a special envelope is opened based on the card inside the patient in group A. (White card) or group B (black). The similarity of the two groups in terms of age, sex, underlying disease and drugs received (patients with moderate lung involvement, symptomatic therapy with painkillers (acetaminophen), antihistamines (diphenhydramine), vitamins C and D) will be statistically evaluated. , Blinding description: To blind a colleague, another doctor will be in charge of assigning patients. The statistician will also be unaware of the intervention and control group and will conduct the study in two groups A a. 2 COVID-19. Intervention 1: Intervention group: A Participants with usual treatment (curcudone 35 mg daily, vitamin C loan 500 mg daily, heparin 5000 units every 12 hours, dexamethasone 4 mg IV daily), pentoxifylline 400 mg daily every 12 hours they receive. Intervention 2: Control group: Participants in this group receive the usual treatment (curcudone 35 mg daily, vitamin C loan 500 mg daily, heparin 5000 units every 12 hours, dexamethasone 4 mg IV daily). Yes - There is a plan to make this available What will be shared: Others researchers can access via the co responder email When: 6 months afters publish article of research To whom: Academic researchers Conditions: More research Where to obtain: Others researchers can access via the co responder email How to obtain: Others researchers can access via the co responder email Comments:
public Sedeqe Sadat Akhlaghi
Assistant Professor of Education, Ayatollah Taleghani Hospital, First floor, Next to the Hemodialysis Department of Taleghani Hospital, Arab Street, Yemen Street, Shahid Chamran Highway, Tehran, Iran
Tehran Iran (Islamic Republic of) 1985717413 +98 21 2303 1335 sediqakhlaghi@yahoo.com Shahid Beheshti University of Medical Sciences scientific Sedighe Sadat Akhlaghi
Assistant Professor of Education, Ayatollah Taleghani Hospital, First floor, next to the Hemodialysis Department of Taleghani Hospital, Arab Street, Yemen Street, Shahid Chamran Highway, Tehran, Iran
Tehran Iran (Islamic Republic of) 1985717413 +98 21 2303 1335 sediqakhlaghi@yahoo.com Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) Positive test of PCR test COVID-19 ََAge more than 18 SpO2 more than 90% no limit no limit Both Sever COVID-19 Need for treatment with Mechanical ventilation Need for treatment with high dose corticosteroids Nausea and vomiting and GIB J96.01 Acute respiratory failure with hypoxia Treatment - Drugs Treatment - Drugs Intervention group: A Participants with usual treatment (curcudone 35 mg daily, vitamin C loan 500 mg daily, heparin 5000 units every 12 hours, dexamethasone 4 mg IV daily), pentoxifylline 400 mg daily every 12 hours they receive. Control group: Participants in this group receive the usual treatment (curcudone 35 mg daily, vitamin C loan 500 mg daily, heparin 5000 units every 12 hours, dexamethasone 4 mg IV daily). Spo2. Timepoint: 1st, 7th, 28th, 35th day. Method of measurement: Pulseoximetry. Shahid Beheshti University of Medical Sciences Approved 2022-05-19 Organizational Committee of Ethics in Biomedical Research Ayatollah Taleghani Hospital, Shahid Arabi St, Yemen St. Shahid Chamran Highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)